Which cardiac surgical patients can benefit from placement of a pulmonary artery catheter? by Ranucci, Marco
Page 1 of 8
(page number not for citation purposes)
Available online http://ccforum.com/content/10/S3/S6
Abstract
The use of pulmonary artery catheters (PACs) during cardiac surgery
varies considerably depending on local policy, ranging from use in
5–10% of the patient population to routine application. However, as
in other clinical fields, recent years have witnessed a progressive
decline in PAC use. One of the reasons for this is probably the
increasing use of transoesophageal echocardiograpy, even though
careful analysis of the information provided by PAC and trans-
oesophageal echocardiograpy indicates that the two tools should be
considered subsidiary rather than alternatives. The principal
categories of cardiac patients who can benefit from PAC monitoring
are those with present and those with possible haemodynamic
instability. On this basis we can identify five groups: patients with
impaired left ventricular systolic function; those with impaired right
ventricular systolic function; those with left ventricular diastolic
dysfunction; those with an acute ventricular septal defect; and those
with a left ventricular assist device. This review highlights the specific
role of PAC-derived haemodynamic data for each category.
Introduction
Placement of a pulmonary artery catheter (PAC) is an
intraoperative right heart catheterization procedure. It therefore
provides clinical information on heart chamber pressures, blood
flows and vascular resistances – similar to the information
obtained during a catheterization laboratory investigation
before the operation. Unsurprisingly, since the inception of the
PAC cardiac pathology has been its natural ‘battlefield’ [1], and
cardiac surgery is the natural setting in which is it applied.
By definition, the cardiac surgical patient always has
underlying cardiac pathology; such pathology can affect
intracardiac pressures and/or myocardial ability to sustain
adequate cardiac output. As a consequence of the underlying
pathology and/or use of specific drugs, the patient can exhibit
changes in systemic and pulmonary resistive state. Moreover,
the cardiac surgery itself may result in sudden changes in
systolic and diastolic right or left ventricular function, and
cardiopulmonary bypass (CPB) may induce release of
vasoactive mediators that change flow resistances at the level
of the systemic or pulmonary circulation. Finally, the common
intraoperative and postoperative use of drugs that act
potently on myocardial contractility, and that induce systemic
or pulmonary vasodilatation or vasoconstriction permits
control of the patient’s haemodynamic profile both during and
after the operation.
In spite of this, and for several reasons, PACs are not
routinely used in all cardiac surgical institutions or in all
cardiac surgical patients. The present review addresses the
present situation regarding use of PACs in cardiac surgery,
and defines those categories of cardiac surgical patients that
may truly benefit from PAC placement.
Use of pulmonary artery catheters in cardiac
surgery: the evidence-based approach
In 1997 a consensus conference PACs [2] was convened to
address the issue of PAC use in different clinical scenarios.
In the setting of cardiac surgery it was agreed that clinical
management with PACs does not improve outcome in low-
risk cardiac surgical patients (grade C), plays an uncertain
role in high-risk patients (grade C), plays an uncertain role in
low-risk patients undergoing aortic surgery (grade B), and
improves outcomes in high-risk patients undergoing aortic
surgery (grade E). These assertions highlight a clinical
scenario that has probably changed since the findings of the
consensus conference were reported. They nevertheless
offer a good starting point; they do not advocate ‘routine’ use
of PACs in cardiac surgery but attempt to define the optimal
patient selection.
However, the findings of two studies published immediately
before [3] and after [4] the consensus conference was held
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resulted in a different interpretation, based on use of the PAC
to assess oxygen-derived haemodynamic variables and to
guide goal-directed therapy. In the first of the two studies,
Polonen and coworkers [3] demonstrated that prolonged
intensive care unit stay following cardiac surgery was
associated with an increase in whole body oxygen extraction,
reflecting a mismatch between the whole body oxygen
demand and supply. In the second study the same authors
[4] demonstrated that therapy targeted at optimizing oxygen
delivery (DO2) immediately after cardiac surgery reduced the
lengths of the stay in the intensive care unit and hospital.
Both studies included an unselected patient population,
raising doubt that even low-risk cardiac surgical patients
could benefit from PAC use.
Despite such findings, many institutions continue to use
PACs routinely in cardiac surgical patients. In a survey
conducted in 1998 in 30 large cardiac surgical institutions in
the USA, Schwann and coworkers [5] found that 67% of
programmes included routine use of PACs in coronary artery
bypass grafting (CABG). In Europe there is a greater
tendency to select patients for PAC use; in our own survey
(data available on request) we estimated that, in 2004, about
20% of Italian cardiac surgical institutions were routinely
using PACs for cardiac operations, whereas the remaining
80% were following various forms of patient selection. A
recent article [6] reported an impressive decrease in PAC
use in cardiac surgery in Japan, from 100% in 1997 to less
than 10% in 2001.
Therefore, at present one can conclude that the indications
for PAC insertion in cardiac surgery vary greatly from
country to country and from institution to institution.
However, it seems reasonable to conclude that there is a
general trend in cardiac surgery, which is reflected by a 9%
fall in PAC sales all over the world [7]. This reduction is
probably due to recent, highly publicized studies [8-11] that
found either no benefit from or even worse outcomes
associated with PAC use. Moreover, during the past
decade the PAC has had to contend with a strong
competitor in the cardiac surgical setting, namely
transoesophageal echocardiography (TEE).
The perpetual debate: pulmonary artery
catheter versus transoesophageal
echocardiography
TEE is currently employed as a monitoring tool and is widely
applied during and after cardiac surgery. Two-dimensional
TEE provides valuable images of the heart and great vessels,
and its roles in assessing valve function, right and left
ventricular contractility, and left ventricular diastolic function
are well established. By combining the two-dimensional view
with a continuous or pulsatile Doppler study, TEE is
theoretically able to provide information about cardiac
chamber pressures, transvalvular pressure gradients and
cardiac output.
Table 1 summarizes haemodynamic data with respect to
availability and reliability of measurement with PAC and TEE
monitoring. Clearly, it is difficult to consider the two tools
‘competitors’. Indeed, all data pertaining to pressures,
resistances and flows are more reliably determined using a
PAC. The only pressure that can be assessed reliably with
TEE is the systolic pulmonary pressure (in the presence of
tricuspid valve regurgitation). The left atrial pressure may be
assessed in the presence of mitral valve regurgitation but with
an unacceptable level of approximation. However, in a recent
article Diwan and coworkers [12] reported a noninvasive way
to determine left ventricular filling pressure in patients with
mitral valve disease, using the isovolumetric relaxation time,
and the time interval between the onset of early diastolic
mitral inflow velocity and annular early diastolic velocity
(assessed using tissue Doppler imaging). Furthermore, they
demonstrated that the indices obtained with this approach
are predictive of pulmonary capillary wedge pressure
(PCWP). This very sophisticated technique clearly requires
much expertise and technical equipment, and its application
is difficult in an intraoperative setting.
In a recent article Oh [13] suggested that echocardiography
is a potential ‘noninvasive Swan-Ganz catheter’, indicating
that PAC is still the reference technique. One of the most
important haemodynamic variables during and after a cardiac
operation is the cardiac output. It is feasible to measure this
parameter using TEE but it has limitations; the general
consensus is that it is strongly operator dependent and less
reliable than the thermodilution technique. It has been
suggested that cardiac output, as measured using TEE, is
better suited to monitoring trends than it is to providing
absolute values [14-16].
The PAC is superior in the fields of pressures, flows and
resistances, but it is well accepted that TEE provides a good
profile of left ventricle size, ejection fraction (EF), fractional
area changes and shortening fraction. It is not possible to
measure these systolic function indices using a PAC. With
respect to the right ventricle, some information is available
using TEE and some from the modified volumetric PAC, with
both techniques being relatively unreliable because of the
peculiar shape of the right ventricle (for TEE) and the
technical limitations of thermodilution-based determination of
right ventricular EF [17].
Diastolic dysfunction can be diagnosed and graded only
using TEE. Fluid responsiveness is better defined by TEE-
derived variables (left ventricular end-diastolic area, peak
blood velocity variation) [18-21], but some information can be
derived from the PAC as well (PCWP and peak pulmonary
pressure variation) [22].
Finally, unlike TEE, the PAC allows measurement of mixed
venous oxygen saturation (SvO2), and consequently the derived
oxygen delivery and consumption variables. These variablesPage 3 of 8
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have a well defined role in assessment of haemodynamic status
in patients undergoing cardiac surgery [3,4].
TEE is a valuable monitoring technique both during and after
cardiac surgery. However, its limitations are that it is a
semiquantitative method and it does not permit continuous
monitoring.
At present, cardiac anaesthesiologists’ choice of PAC or TEE
monitoring is strongly influenced by their expertise with and
availability of TEE. In 2002 a large survey conducted in
Canada [23] revealed that use of the PAC remained the
preferred monitoring technique among cardiovascular
anaesthesiologists.
In conclusion, PAC and TEE are not competitors. Rather, they
are subsidiary tools. High-risk patients may benefit from the
use of both. My personal feeling is that the more I use TEE,
the more I use the PAC.
Selecting cardiac surgical patients for
pulmonary artery catheter placement
If we accept that the PAC should not routinely be used in
cardiac surgery (although this is debatable), then selection of
patients should be guided by their risk profile. In this regard, the
available scoring systems appear to unsuitable. A patient could
belong to a high-risk group because of various noncardiac
pathologies (diabetes, lung disease, peripheral arteriopathy,
neurological dysfunction, and others); these comorbidities do
not necessarily represent a good reason to use a PAC. It is
preferable that decisions be guided by haemodynamic status,
as indicated by conditions such as left ventricular systolic
and/or diastolic dysfunction, low output state, need for left
ventricular reshaping, right ventricular dysfunction, pulmonary
hypertension, need for mechanical circulatory support and
mechanical complications of acute myocardial infarction (MI).
In a recent survey Jacka and coworkers [24] investigated the
appropriateness of PAC use in cardiac surgery according to
Available online http://ccforum.com/content/10/S3/S6
Table 1
Haemodynamic data availability and reliability with PAC and TEE
PAC TEE
Parameter Feasibility Reliability Feasibility Reliability
SvO2 Yes +++ No
CVP Yes +++ No
PAP Yes +++ Possible if TR ++
LAP (wp) Yes ++ Possible if MR +
CO Yes +++ Yes +
SV Yes +++ Yes +
Systemic resistance Yes +++ Yes +
Pulmonary resistance Yes +++ Yes +
RVEDV Yes + Yes +
Right ventricular EF Yes + Yes +
LVEDV No Yes ++
Left ventricular EF No Yes ++
Left ventricular FAC No Yes +++
Left ventricular SF No Yes +++
Delta SV No Yes +++
Delta peak pressure Yes (pulmonary) +++ No
Peak velocity changes No Yes +++
Valve function No Yes +++
Fluid responsiveness Yes + Yes +++
Diastolic function No Yes +++
CO, cardiac output; CVP, central venous pressure; EF, ejection fraction; FAC, fractional area change; LAP, left atrial pressure; LVEDV, left
ventricular end-diastolic volume; MR, mitral regurgitation; PAC, pulmonary artery catheter; PAP, pulmonary artery pressure; RVEDV, right ventricular
end-diastolic volume; SF, shortening fraction; SV, stroke volume; SvO2, mixed venous oxygen saturation; TEE, transoesophageal echocardiography;
TR, tricuspid regurgitation; wp, wedge pressure.345 Canadian cardiac anaesthesiologists. Left ventricular
impairment was considered an appropriate indication by 74%
of the anaesthesiologists, unstable angina by 55%, and the
presence of both the previous factors was considered an
appropriate indication by 87% of the anaesthesiologists. In
the same year, Schwann and coworkers [5] identified six
independent predictors for use of PACs in CABG surgery:
EF, STS risk score, intra-aortic balloon pump, congestive
heart failure, redo surgery and New York Heart Association
functional class IV.
It therefore appears generally accepted that a condition
involving haemodynamic risk is the best indicator for use of a
PAC during cardiac surgery. On this basis, and according to
my personal experience, I have identified five categories of
patients who may benefit from the intraoperative placement of
a PAC.
Patients with severely depressed left ventricular
systolic function
From a clinical perspective, these patients belong to the
group that is identified in many risk scoring systems as
‘preoperative EF <0.30’. This group is becoming larger as
the clinical condition of cardiac surgical patients deteriorates.
Moreover, in recent years there has been a growing tendency
to conduct surgical reshaping of the post-ischaemic dilated
left ventricle, which means conducting surgery in patients
with an EF of even less than 0.2 [25,26].
Patients with severely depressed left ventricular systolic
function usually enter the operating room receiving a cocktail
of drugs including diuretics and vasodilators. They often
maintain an acceptable perfusion pressure as a result of
compensatory peripheral vasoconstriction. Once anaesthesia
is induced, this delicate balance between myocardial
contractility, intravascular filling and peripheral resistance may
be disturbed, leading to hypotension. Conversely, the
presence of a normal blood pressure does not guarantee
adequate cardiac output. In this scenario, the PAC may offer
a great deal of clinically relevant information.
Before establishing cardiopulmonary bypass
Before CPB is established, data from the PAC may be used
to determine the cardiac output of the patient, and to control
left ventricular filling pressures (PCWP). PAC data may also
be used to control the pulmonary artery pressure (PAP) in
order to identify the presence of pre-capillary or post-capillary
pulmonary hypertension; if pre-capillary hypertension is
excluded, PAP may be used as a continuous indicator of LV
filling. The PAC can be used to assess systemic vascular
resistance. Finally, it can be used to measure the SvO2 in
order to verify the adequacy of DO2 with respect to oxygen
consumption.
All this information should be integrated to derive a goal-
orientated therapeutic strategy, aimed at maintaining ‘normal’
cardiovascular physiology (i.e. cardiac index >2.4) through
use of intravascular fluid filling, inotropes and vasodilators.
From this perspective, some indices should be considered
the clinical ‘target’ and others should be considered markers
of the physiological reserve and of the physiological response
to treatment.
Immediately after cardiopulmonary bypass and during the
early postoperative course
During this period almost invariably these patients need
inotropic/vasoactive support and strict control of left
ventricular preload. The use of an intra-aortic balloon pump is
common, and sometimes a ventricular assist device is
needed to wean the patient from CPB. Therefore, all of the
considerations during the pre-CPB to ensure that the
patient’s haemodynamic profile is optimal remain valid
subsequently. In my opinion, particular attention should be
directed at intravascular filling; patients with depressed left
ventricular systolic function are to the right of the Starling
diagram, where the preload-generating force is almost
exhausted and where inadequate left ventricular filling may
result in low cardiac output or, conversely, excessive filling
may provoke pulmonary vascular congestion. Therefore, the
fluid responsiveness of the patient should be carefully
assessed. Indeed, PCWP has been replaced by echo-
derived indices of preload (i.e. left ventricular end-diastolic
area) [21], by Doppler-derived indices [18] and certainly by
dynamic indices such as peak pressure variation and aortic
blood velocity variation [27,28]. However, almost all authors
agree that a ‘fluid responder’ is a patient who reacts to a fluid
change with a certain increase in stroke volume. It is therefore
clear that the best and most reliable marker of fluid
responsiveness is a PAC-derived parameter; moreover,
despite its relatively low specificity and sensitivity, careful
monitoring of PCWP during fluid administration may help in
avoiding pulmonary circulation overload.
Finally, one of the most important goals in treating these
patients is to optimize their haemodynamics, aiming to match
DO2 to oxygen consumption and so avoid lactic acidosis.
High levels of blood lactate have been observed during and
after cardiac surgery [29,30], and this has been associated
with various adverse outcomes. Conversely, a goal-orientated
approach, aimed at maintaining high levels of DO2, was
associated with a better outcome [4]. Therefore, it may be
concluded that, throughout the intraoperative and
postoperative course of high-risk cardiac surgery, patients
should be afforded constant (possibly continuous with the
new generation of PACs) monitoring of SvO2 because it is a
useful marker of cardiac output adequacy.
Patients with impaired right ventricular function
The PAC is a right-sided heart catheter, and unsurprisingly it
offers much clinical information on the right ventricle and
pulmonary vascular status. Implemented with a specific
algorithm (additionally requiring the heart rate), the
Critical Care    Vol 10 Suppl 3 Ranucci
Page 4 of 8
(page number not for citation purposes)thermodilution principle permits measurement of the right
ventricular EF and its derivative right ventricular end-diastolic
volume (RVEDV). This ‘volumetric PAC’ is presently available
for continuous monitoring. However, this measurement is
reliable only in the absence of tricuspid regurgitation [17],
and its role and clinical importance are still debated [31-33].
Right ventricular dysfunction is quite common in patients
before and after cardiac surgery. Basically, the right ventricle
may be affected by previous ischaemic damage or it may
develop an acute right ventricular myocardial infarction during
or after cardiac surgery. Also, because it is a volumetric
pump, the function of the right ventricle may be severely
impaired by pulmonary hypertension. Pulmonary hypertension
and right ventricular dysfunction following CPB can result in
failure to wean from CPB, and acute right ventricular failure
can be life threatening [34]. The discrimination between right
ventricular failure with and that without pulmonary
hypertension is of paramount importance therapeutically; in a
recent consensus conference [35] a group of European
experts recommended the use of inhaled nitric oxide only in
presence of pulmonary hypertension.
In the presence of a low output state resulting from right
ventricular failure, during or after cardiac surgery, the most
reliable diagnostic tool is of course TEE. However, the PAC is
able to quantify the degree of the low cardiac output state
and define the pathophysiological scenario (i.e. it can be
used to assess PAP and PCWP). Most importantly, however,
is that it allows one to follow changes in haemodynamic
pattern and to use this information to guide fluid administra-
tion and inotropic therapy, and to identify changes in
pulmonary pressures resulting from inhaled nitric oxide
therapy and/or mechanical ventilatory support.
The most important data obtained from the PAC in this
setting are as follows: cardiac output and SvO2, PAP and
PCWP, central venous pressure, and right ventricular EF and
RVEDV. Cardiac output helps in grading the severity of the
patients clinical condition, and SvO2 allows to quantify its
adequacyto metabolic needs. PAP and PCWP may be used
to identify the presence of pre-capillary or post-capillary
pulmonary hypertension and follow the effects of pulmonary
vasodilatory therapy. Central venous pressure is an index of
right ventricular preload and global venous filling. Finally, right
ventricular EF and RVEDV (with the previously mentioned
limitations) may be used as indices of right ventricular
contractility and preload.
Patients with left ventricular diastolic dysfunction
The diagnosis and grading of diastolic dysfunction are
typically within the domain of TEE. However, some valuable
and clinically relevant information may be obtained with the
use of a PAC. Diastolic dysfunction may be graded based on
a combination of Doppler-derived data [36]. The first degree
of diastolic dysfunction (impaired relaxation) is usually seen
after weaning the patient from CPB, and is often reversible.
The second degree (pseudo-normalization) is a more severe
condition, which sometimes is an intermediate step toward
the third degree (restrictive pattern). In the latter condition the
Doppler study is characterized by an increased ratio (>2)
between E and A waves of mitral flow, and by a blunted
systolic waveform of the pulmonary vein flow. Both of these
conditions result from increased left atrial pressure. It has
been demonstrated that both mitral flow and pulmonary vein
flow indices are correlated with the PCWP. Therefore,
measurement of PCWP may be of value in assessing the time
course of diastolic dysfunction and the effect of therapeutic
manoeuvres.
Among the various pathological features that lead to diastolic
dysfunction, a rather interesting pattern is that represented by
hypertrophic cardiomyopathy (whether idiopathic or resulting
from aortic valve stenosis). In this setting the main problem is
supplying the left ventricle with adequate preload; it is quite
typical to find an echo-derived low preload (i.e. very low left
ventricular end-diastolic area) with a concomitant PAC-
derived sign of elevated filling pressures (i.e. high PCWP).
Such patients need volume, but every fluid administration
should be carefully guided by constant measurement of
PCWP, in order to avoid an abrupt increase in pulmonary
venous pressure with consequent congestive heart failure.
Acute ventricular septal defect
Acute ventricular septal defect (VSD) is a severe
complication of myocardial infarction. When present, it is
associated with high mortality rates. Opinions on the correct
timing of the repair operation differ, but the only therapeutic
option is closure of the VSD, either surgically or by applying
specific closing devices in the catheterization laboratory. In
both cases, the insertion of a PAC is mandatory; because the
rate VSD reopening after both procedures is considerable,
the PAC is a potent diagnostic tool. SvO2 is a valuable and
rapid marker of left-to-right shunt, and in presence of
abnormally high values an echo study may confirm the
presence of the shunt.
Left ventricular assist device
A left ventricular assist device (LVAD) may be used in the
setting of cardiac surgery, for treatment of refractory
postoperative heart failure, or as a bridge to recovery or to
transplantation. LVADs unload the left ventricle and decrease
left atrial pressure; however, they simultaneously increase right
ventricular preload. In this specific pathophysiological
situation, LVAD flow is completely sustained by the right
ventricle, which is responsible for effective filling of the device.
Unfortunately, right ventricular dysfunction that is refractory to
conventional pharmacologic therapy occurs in 20–40% of
patients supported with a LVAD. The role played by pulmonary
resistance is of great importance. If resistances are normal
then the LVAD decreases the right ventricular afterload and
aids right ventricular function; in the case of pulmonary
Available online http://ccforum.com/content/10/S3/S6
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ventricle is unable to fill the LVAD adequately [35]. Right
ventricular failure in patients with LVAD is a severe condition
that leads to high rates of mortality [37,38].
I believe that patients with a LVAD may derive particular
benefit from PAC monitoring. The most important information
in this setting comes from right-sided pressures and volumes:
central venous pressure, right ventricular EF and RVEDV are
all markers of right ventricular function during left heart
assistance; and PAPs are diagnostic of pulmonary vascular
resistance status, and may guide the choice of a selective
(inhaled nitric oxide) pulmonary vasodilator [35].
Summary of pulmonary artery catheter derived
haemodynamic data
Table 2 summarizes the usefulness and clinical meaning of
the various PAC-derived haemodynamic data in the five
categories of patients. There probably are other clinical
scenarios in which PAC placement may be considered
Critical Care    Vol 10 Suppl 3 Ranucci
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Table 2
Clinical meanings and usefulness of various PAC-derived haemodynamic variables in different clinical conditions
Useful PAC-
Clinical scenario derived indices Clinical meaning/uses
Impaired left ventricular  CI Clinical target (i.e. >2.4 l/min per m2)
systolic function Monitor effects of inotropic therapy
Monitor fluid responsiveness
PCWP Left ventricular filling pressure
Monitor fluid responsiveness
Monitor effects of inotropic/vasodilating therapy
PAP Check for the presence of pre-capillary or post-capillary pulmonary hypertension
Possible use as continuous index of left ventricular preload
SVR Check for the presence of a peripheral vasoconstrictive status
SvO2 Monitor the effects of vasodilating therapies
Clinical target (i.e. >75%)
Check matching of DO2 to VO2
Monitor adequacy of CI
Monitor the effects of drug and fluid administration
Impaired right ventricular function CI As above
SvO2 As above
PCWP As above
CVP RV preload and venous system filling status
Monitor fluid responsiveness
PVR Check for the presence of pulmonary hypertension
Guide inhaled nitric oxide therapy and ventilator settings
Right ventricular EF RV contractility index
RV EDV RV preload 
Left ventricular diastolic dysfunction CI As above
SvO2 As above
PCWP As above, with particular respect to fluid responsiveness and fluid administration
Follow changes from pseudo-normalization to restrictive pattern
Acute ventricular septal defect CI Suggestive for VSD reopening after correction if increased
SvO2 Diagnostic for VSD reopening after correction if increased
LVAD CVP Right ventricular preload and general filling status of the patient
PVR Presence of pre-capillary pulmonary hypertension
Need for iNO therapy and monitor the effects
Right ventricular EF Right ventricular contractility and preload
RVEDV
SvO2 Adequacy of LVAD flow to the metabolic needs
CI, cardiac index; CVP, central venous pressure; DO2, oxygen delivery; EF, ejection fraction; LVAD, left ventricular assist device; PAC, pulmonary
artery catheter; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistances; RVEDV; right
ventricle end-diastolic volume; SvO2, mixed venous oxygen saturation; SVR, systemic vascular resistances; VO2, oxygen consumption.appropriate. For example, many institutions consider PAC
placement mandatory for intraoperative monitoring of patients
undergoing off-pump CABG surgery. However, as indicated
at the start of the present review, cardiac surgery represents
a clinical field in which, depending on local policy, PAC use
may range from 0–5% of the patient population up to 100%.
Conclusion
Cardiac surgery is probably a clinical field in which we should
all agree with Pinsky and Vincent [7]: ‘Let us use the
pulmonary artery catheter correctly and only when we need
it.’ Of course, the definition of what represents correct use
and a correct indication may vary depending on local policy,
economic considerations, the patient population and, most of
all, the specific expertise of the medical and nursing staff.
With regard to the latter, adequate training as to the
pathophysiological meaning of this monitoring and diagnostic
tool should be given and periodically refreshed so that all of
the potential benefits of the PAC can be realized while
avoiding potential misuse.
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